Preclinical Characterization and Phase I Trial Results of a Bispecific Antibody Targeting PD-L1 and 4-1BB (GEN1046) in Patients With Advanced Refractory Solid Tumors.
Sign Up to like & getrecommendations! Published in 2022 at "Cancer discovery"
DOI: 10.1158/2159-8290.cd-21-1345
Abstract: Checkpoint inhibitors (CPIs) have revolutionized the treatment paradigm for advanced solid tumors; however, there remains an opportunity to improve response rates and outcomes. In preclinical models, 4-1BB costimulation synergizes with CPIs targeting the PD-1/PD-L1 axis… read more here.
Keywords: patients advanced; gen1046; 1bb gen1046; solid tumors ... See more keywords